Name

CinnaGen

Legal name

CinnaGen

Website

https://cinnagen.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Biopharmaceutical products
• Biosimilar medicines
• Therapeutic biologics
• Monoclonal antibodies
• Specialty pharmaceuticals

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical Product Sales: Revenue generated from the sale of approved biologic drugs including biosimilars. With EU marketing authorization for Zandoriah®, the company can now commercialize products across EU member states through local distribution partners.
2. Licensing and Partnership Agreements: Revenue from licensing biosimilar products to commercial partners for distribution in various markets, as evidenced by their approach to country-level launches across European markets.

Go-to-market motion1 record

Distribution channels1 record

Core offering

CinnaGen develops, manufactures, and commercializes biologic and biosimilar pharmaceutical products across six therapeutic areas: neurology and ophthalmology, oncology and hematology, endocrinology and infertility, autoimmune and immunology, rare metabolic and genetic diseases, and infectious diseases. The company operates the full biopharmaceutical value chain from research and development through clinical trials and EU-GMP-compliant production, with its lead international product Zandoriah® (teriparatide biosimilar) approved for marketing across the European Union for the treatment of osteoporosis in adults.

Product overview

CinnaGen is an Iranian biopharmaceutical company offering a diverse portfolio of products across six therapeutic categories: Neurology and Ophthalmology, Oncology and Hematology, Endocrinology and Infertility, Autoimmune and Immunology, Rare Metabolic and Genetic Diseases, and Infectious Diseases. The company develops both innovative biologics and biosimilars. Notable products include Zandoriah®, a teriparatide biosimilar for osteoporosis approved in the EU in 2026. CinnaGen operates across the full biopharmaceutical value chain including research and development, production, and clinical trials, with EU-GMP manufacturing standards.

Differentiator

Problem solved

Functional benefit

Brands

• Zandoriah: Teriparatide biosimilar for treatment of osteoporosis in adults
• CinnaGen Beyond Borders

Products and services

• Neurology and Ophthalmology Products
• Oncology and Hematology Products
• Endocrinology and Infertility Products
• Autoimmune and Immunology Products
• Rare Metabolic and Genetic Diseases Products
• Infectious Diseases Products
• Zandoriah® (teriparatide biosimilar)

Quantifiable outcome

• Marketing authorization across all 27 EU member states plus Iceland, Liechtenstein, and Norway

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Commercial Partners (European Markets)coreChannel Partner/ Reseller/ DistributorCinnaGen is working with commercial partners to plan and execute country-level launches of Zandoriah® across European markets. These partners handle local market access, pricing negotiations, and reimbursement arrangements within their respective territories.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Samsung Bioepis: South Korean biosimilar specialist developing and commercializing biosimilars across multiple therapeutic areas including immunology and oncology. Highly comparable to CinnaGen's biosimilar-led, multi-therapeutic strategy and partnership-driven international commercialization model.
• Celltrion: Korean biopharma with leading biosimilar portfolio (Remsima/Inflectra, Truxima, Herzuma) and EMA-approved products sold globally through partners. Closest peer to CinnaGen in terms of biosimilar breadth, regulatory sophistication, and partner-led international rollout.
• Biocon Biologics: Indian biosimilar developer with EMA-approved products (insulin glargine, trastuzumab, bevacizumab biosimilars) commercialized through partners including Viatris. Comparable to CinnaGen as a cost-competitive emerging-market biosimilar manufacturer with growing EU presence.
• Alvotech: Iceland-based biosimilar company focused on monoclonal antibody biosimilars with EMA approvals and partner-led commercialization. Directly comparable to CinnaGen in scale, biosimilar focus, partner-driven go-to-market, and reliance on quality manufacturing certification.
• mAbxience: Spanish biosimilar company (Insud Pharma group) developing and manufacturing monoclonal antibody biosimilars for global markets. Comparable as a mid-sized biosimilar manufacturer pursuing EMA approvals through partner channels.

Broad incumbents

• Sandoz: Global leader in biosimilars and generics, spun out from Novartis, with deep EMA-approved biosimilar portfolio across multiple therapeutic areas. Represents the dominant incumbent that CinnaGen's biosimilars will compete against in EU tenders and reimbursement negotiations.
• Amgen: Major biopharma with both originator biologics and an EMA-approved biosimilar portfolio (e.g., Amgevita, Kanjinti). Represents an established biosimilar competitor with deep commercial infrastructure that CinnaGen will encounter in tender processes.
• Viatris: Global biopharma with a broad biosimilar portfolio developed in partnership with Biocon and others. Comparable as both a potential CinnaGen distribution partner and a competitive biosimilar supplier in EU markets.
• STADA Arzneimittel: European generics and biosimilars company with established EU commercial footprint and growing biosimilar portfolio. Comparable as an EU-focused mid-to-large biosimilar and specialty pharma player, and a potential commercial partner for CinnaGen in select EU territories.

Emerging players

• Polpharma Biologics: European biosimilar developer with biosimilar programs across immunology, oncology, and ophthalmology, and partner-led commercialization. Comparable emerging biosimilar peer with similar therapeutic breadth and partnership GTM model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CinnaGen